Cancer immunotherapy works by stimulating and strengthening the body's anti-tumor
immune response to eliminate cancer cells. Over the past few decades, immunotherapy has …

Abstract mRNA-based drugs have tremendous potential as clinical treatments, however, a
major challenge in realizing this drug class will promise to develop methods for safely …

Many approaches to identify therapeutically relevant neoantigens couple tumor sequencing
with bioinformatic algorithms and inferred rules of tumor epitope immunogenicity. However …

Neoantigens are peptides derived from non-synonymous mutations presented by human
leukocyte antigens (HLAs), which are recognized by antitumour T cells,,,,,,,,,,,,–. The large …

Recent advances in neoantigen research have accelerated the development and regulatory
approval of tumor immunotherapies, including cancer vaccines, adoptive cell therapy and …

Immune-checkpoint inhibition provides an unmatched level of durable clinical efficacy in
various malignancies. Such therapies promote the activation of antigen-specific T cells …

The use of immunotherapies for the treatment of brain tumors is a topic that has garnered
considerable excitement in recent years. Discoveries such as the presence of a glymphatic …

The interest in therapeutic cancer vaccines has caught enormous attention in recent years
due to several breakthroughs in cancer research, among which the finding that successful …

Immunotherapeutic manipulation of the antitumor immune response offers an attractive
strategy to target genomic instability in cancer. A subset of tumor-specific somatic mutations …

Background The use of next-generation sequencing technologies has enabled the rapid
identification of non-synonymous somatic mutations in cancer cells. Neoantigens are …